Insider Cluster (9 insiders) ·Filed Jun 17, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 9 insiders, $1.2M total
Actionable Insight • Neutral

The insider sales are immaterial in dollar terms—no bearish signal. Monitor for upcoming pipeline or regulatory catalysts, as QURE is a gene therapy biotech with high stock volatility. The recent historical reports show large price swings following prior filings, but this cluster alone does not warrant a directional trade.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
QURE ▼ -14.97% at T+20d
NEUTRAL call ✗ call lost -14.97% · α vs SPY -15.50% · entry $46.29 → $39.36
Next anchor: T+60d due 18d ago
Latest observation: T+57 -35.72% FF3 residual α
Entry anchored
Jun 17, 04:02 PM ET
via exchange tick
T+1d
-4.10%
call -4.10% · α -3.79%
$44.39
settled 4mo ago
T+5d
+6.07%
call +6.07% · α +7.74%
$49.10
settled 3mo ago
T+20d
-14.97%
call -14.97% · α -15.50%
$39.36
settled 3mo ago
T+60d
—
call — · α —
—
due 18d ago

Price Chart

Loading chart...

Executive Summary

Nine insiders at uniQure N.V. (QURE) sold a total of $1.2M in shares over a 7-day window, representing approximately 0.07% of the company's $1.7B market cap. The sales are small relative to company size and include both directors and two C-suite officers (Chief Legal Officer and Chief Customer & Strategy Officer). Despite the cluster of sellers, the dollar amounts are trivial and likely routine, not signaling a material bearish view.

Key Financial Metrics

Direction
selling
Total Value
$1.2M
Insiders
9

Key Facts

  • Total insider sales: $1.2M across 9 insiders in a 7-day window
  • Sales represent only ~0.07% of QURE's $1.7B market cap
  • Participants include Chief Legal Officer ($145K) and Chief Customer & Strategy Officer ($431K), plus 7 directors
  • One director (Balachandran Madhavan) exercised derivatives alongside an open-market sale

Financial Impact

Insider sales total $1.2M, a trivial amount relative to the $1.7B market cap

Risk Factors

  • Low insider selling volume provides no negative signal
  • QURE's stock has shown extreme volatility in past filings (T+20 alpha often >20%)
  • No material financial or operational news accompanies this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-QURE-1781730167729
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (65h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 17, 2026